Phase 4 study of trastuzumab deruxtecan for HER2-positive solid tumors (DP-04)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[D4327R00001] Effectiveness of T-DXd across HER2-positive solid tumors in patients who have received prior systemic treatment and have no satisfactory alternative treatment options: A hybrid observational study
Principal Investigator
Headshot of Aman Opneja
Assistant Professor of Medicine
Protocol Number
IRB: PRO00118385
Phase
Phase IV
Enrollment Status
OPEN TO ACCRUAL
Participate